Researchers at UC Santa Barbara have developed a new way to deliver drugs into cancer cells by exposing them briefly to a non-harmful laser. Their results are published in a recent article in ACS Nano, a journal of the American Chemical Society.
RNAs, serving as a mere intermediary between DNA and proteins, were long regarded as a poor relation by researchers, attracting little interest. However, following the discovery of small RNAs known as microRNAs, they hav...
ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, announced that Tanya Sandrock, PhD, Research + Development scientist, rec...
Xavier University of Louisiana and New York University have received a $3 million grant from the National Science Foundation to bolster diversity among materials scientists through collaborative research and curriculum d...
Important issues surrounding the quality of food and drugs-including global supply chain management, the challenges of creating follow-on biologics (in Canada, subsequent entry biologics) and nanotechnology for drug deli...
Diana-Andra Borca-Tasciuc, assistant professor of mechanical, aerospace, and nuclear engineering at Rensselaer Polytechnic Institute, has won a Faculty Early Career Development Award (CAREER) from the National Science Foundation (NSF).
Putting the next generation of medicines on pharmacy shelves hinges on an intensive search for ways of safely and effectively delivering a silencing message to genes that are at the basis of innumerable diseases. That...
In an advance toward better treatments for the most serious form of brain cancer, scientists in Illinois are reporting development of the first nanoparticles that seek out and destroy brain cancer cells without damaging nearby healthy cells.
A University of Arkansas for Medical Sciences (UAMS) researcher on the cutting edge of nanotechnology has been awarded $2.3 million in three grants to further groundbreaking developments in the prevention of lethal cance...
NanoBio Corp. announced today that data from a large ferret study indicates that its intranasal, nanoemulsion-based adjuvant elicits robust immunity and cross protection against influenza using 1/15th of the standard antigen dose, without evidence of toxicity or tolerability concerns.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.